Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat tosylate plus pembrolizumab versus pembrolizumab alone for first-line advanced or metastatic PD-L1-high NSCLC without driver alterations
CTR20244304Phase 2Terminated
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of valemetostat, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd.. Started Nov 2024; status: terminated.
02
Drugs
valemetostatpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244304.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244304.